Pfizer Inc PFE

$28.52 -0.20 (-0.70%)

Valuation

Market cap
163,694,624,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.42
Forward PE
9.65
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
33,638,900
Avg volume
36,004,695
Day's range
$28.52 – $28.95
Shares out
5,699,674,000
Stochastic %K
74%
Beta
0.34
Analysts
Sell
Price target
$28.92

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

AStrokeOfLuck Sep 30, 11:48 PM
$SPY $XBI $MRK $BMY $PFE a little odd
1 replies
Samishere Sep 30, 10:38 PM 0 replies
Quantumup Sep 30, 7:54 PM
Stifel on $JBIO (Buy; $40): We're reiterating our Buy rating on JBIO following preclinical updates presented at EADV for recently-disclosed JADE301, a half-life extended anti-IFN-ẞ mAb for Dermatomyositis. $PFE $ROIV AZN ARGX OTSKY TVTX VERA ARWR NVS BIIB - RHHBY AMGN Here's what else Stifel had to say in its note to investors: https://x.com/Quantumup1/status/2105385653227721151?s=20
0 replies
SellasgpsCurativeBAT11 Sep 30, 6:31 PM
$AZN $BMY $JNJ $PFE $SLS With Warrants Extinguished and No real resistance can move to the upside very violently. Tis the evening before what we all here have been waiting for. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 30, 6:21 PM
$AZN $BMY $JNJ $PFE $SLS This move up is on very heavy volume. No big resistance till $15.87. ✌️🙏❤️‍🩹
0 replies
biokvint Sep 30, 6:09 PM
$PFE Love it here. My average is 23$
0 replies
SellasgpsCurativeBAT11 Sep 30, 6:02 PM
$AZN $BMY $JNJ $PFE $SLS Ask being chewed up, Big block buys going through Level 2. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 30, 5:33 PM
$ABBV $BMY $JNJ $PFE $SLS Pfizer CEO Dr. Bourla friend of Sellas CEO Dr. Stergiou. Dr. Bourla Cancer is not one disease. It hides, it adapts, it comes back different. That is why the research is so complicated, and why it has remained the greatest challenge in medicine. But the science is breaking, and we can now see opportunities to defeat it that we could not even dream of a few years ago. Going after a problem that big takes focus, and the same is true for all of us, whatever your goal may be. Focus enables ambition. When it is guided by real purpose, you can go further than you ever thought possible. That is why we dedicate the greatest share of our research to cancer, and why I am more optimistic than ever about what that will mean for patients. On #WorldCancerResearchDay, my thanks to every researcher working to get us there. ✌️🙏❤️‍🩹
0 replies